FindTrial
Sign In

STRO-002

DRUG3 trials

Sponsors

Sutro Biopharma, Inc., Tasly Pharmaceutical Group Co., Ltd

Conditions

Endometrial CancerEndometrioid AdenocarcinomaFallopian Tube CancerNeoplasm MalignantOvarian CancerOvarian CarcinomaOvary CancerPrimary Peritoneal Carcinoma

Phase 1

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
CompletedNCT03748186
Sutro Biopharma, Inc.Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer +4
Start: 2019-02-01End: 2024-06-04Updated: 2025-08-20
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
TerminatedNCT05200364
Sutro Biopharma, Inc.Fallopian Tube Cancer, Ovarian Cancer, Ovarian Carcinoma +2
Start: 2022-03-22End: 2025-06-01Updated: 2025-09-22
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
CompletedNCT06238687
Tasly Pharmaceutical Group Co., LtdNeoplasm Malignant
Start: 2023-11-08End: 2025-12-30Updated: 2026-04-06

Related Papers

Data from The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
2025-09-02
The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death
Molecular Cancer Therapeutics2025-04-281 citations
TP021/#1540  Reframe-O1/ENGOT-OV79/GOG-3086: a phase 2/3 open-label study evaluating the efficacy and safety of luveltamab tazevibulin versus investigator’s choice chemotherapy in relapsed platinum-resistant EOC expressing folate receptor-alpha
2023-11-011 citations
Positive Outcomes for Luveltamab Tazevibulin in Ovarian Cancer
Oncology Times2023-07-10
Luveltamab tazevibulin (STRO-002), an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), safety and efficacy in a broad distribution of FolRα expression in patients with recurrent epithelial ovarian cancer (OC): Update of STRO-002-GM1 phase 1 dose expansion cohort.
Journal of Clinical Oncology2023-06-0124 citations
Selected Articles from This Issue
Molecular Cancer Therapeutics2023-02-01
Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers
Molecular Cancer Therapeutics2022-11-3053 citations
Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML
Blood2022-11-156 citations
STRO-002-GM2: A phase 1, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody-drug conjugate (ADC), in combination with bevacizumab in patients with advanced epithelial ovarian cancer (EOC, including fallopian tube or primary peritoneal cancers).
Journal of Clinical Oncology2022-06-017 citations
Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).
Journal of Clinical Oncology2021-05-2011 citations
138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)
Poster2020-11-012 citations
Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers
Cancer Research2020-08-152 citations
Abstract C095: Antitumor activity of STRO-002, a novel anti-folate receptor-α (FRα) antibody drug conjugate (ADC), in patient-derived xenograft (PDX) models and preliminary phase I dose escalation safety outcomes in patients with ovarian carcinoma (OC)
Molecular Cancer Therapeutics2019-12-013 citations
Abstract CT160: A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometrial cancers
Cancer Research2019-07-01
Abstract CT160: A Phase I, open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-002, an anti-folate receptor alpha (FolRα) antibody drug conjugate (ADC), in patients with advanced epithelial ovarian cancer (including fallopian tube or primary peritoneal cancers) and endometrial cancers
Clinical Trials2019-07-01